A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Olaparib (Primary) ; AZD 5363; AZD-1775; Vistusertib
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms OLAPCO
- 24 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 17 Nov 2015 Planned initiation date changed from 1 Oct 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 20 Oct 2015 New trial record